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CDH-1Summary Hereditary diffuse gastric cancer is an autosomal dominant cancer syndrome characterized by
highly penetrant diffuse gastric cancer. It is caused by germ line mutations in CDH1, encoding the cell-
cell adhesion protein E-cadherin. Pancreatic ductal adenocarcinoma is one of the most dismal
malignancies in humans. Although absent E-cadherin expression in pancreatic ductal adenocarcinoma is
related to a higher tumor grade and a worse prognosis, there have been no reports of pancreatic ductal
adenocarcinoma associated with hereditary diffuse gastric cancer. Here, we describe a patient with
hereditary diffuse gastric cancer who was subsequently diagnosed with pancreatic ductal adenocarci-
noma. To investigate if the previously identified CDH1 germ line mutation initiated pancreatic ductal
adenocarcinoma development, we performed mutational and proteomic analyses. We conclude that the
pancreatic ductal adenocarcinoma did not occur in the context of the germ line CDH1 mutation but
rather appeared as a sporadic event. Immunohistochemistry ultimately proved to be the most valuable
tool of investigation as persistent CDH1 staining in the pancreatic ductal adenocarcinoma unequivocally
revealed E-cadherin expression.
© 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Hereditary diffuse gastric cancer (HDGC) is an autosomal
dominant cancer syndrome [1] characterized by diffuse
gastric cancer (DGC) that presents with high penetrance. The⁎ Corresponding author.
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83% in women by the age of 80 years [2]. The CDH1 gene,
encoding E-cadherin, is the only known gene associated with
HDGC, and in 25% to 50% of patients with HDGC, a germ
line mutation in CDH1 has been identified. To date,
approximately 100 different germ line mutations in CDH1
have been described in more than 150 HDGC families [3,4].
Because of the high penetrance, aggressive behavior, and
difficulty of detecting tumor on surveillance endoscopy, a
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germ line mutation carriers [5]. This operation is carried out
in the third decade of life.
Pancreatic ductal adenocarcinoma (PDAC) is known
for its poor prognosis, with a 5-year survival of less than
5% and a median survival of only 6 months [6]. Because
most patients present with locally advanced or distant
metastatic disease, palliative treatment is often the only
viable option. Only 10% to 20% of patients with PDAC
qualify for surgical resection, which remains the only
curative treatment. Of note, many sporadic mutations have
been described in PDAC, including mutations in the
KRAS2 oncogene and the tumor suppressor genes
CDKN2A/p16, TP53, and SMAD4 [7]. With respect to
E-cadherin in PDAC, loss of expression is related to a
higher tumor grade and a worse prognosis [8]. However,
there have been no reports of a PDAC in association with
HDGC. Moreover, there is as yet no evidence for an
increased risk of PDAC in patients with a germ line
CDH1 mutation.
In this case report, we describe a patient recently
diagnosed with PDAC who harbored a previously
identified CDH1 germ line mutation and had a history of
multifocal intramucosal diffuse gastric carcinoma that was
diagnosed in the prophylactic gastrectomy specimen. To
investigate whether the pancreatic tumor was related to the
germ line CDH1 mutation, we performed immunohisto-
chemistry (IHC) for E-cadherin on the gastric tumor, the
pancreatic tumor, and normal control tissue. Moreover,
extensive mutation and methylation analysis was per-
formed in search of the “second genetic hit,” which may
have eliminated CDH1 signaling. Furthermore, to further
characterize the PDAC, KRAS2, and TP53 mutation,
analysis was performed on the pancreatic tumor samples.2. Case history
A 56-year-old man presented to the emergency
department with intense epigastric pain, diarrhea, and
dark urine. Physical examination revealed jaundice and a
palpable liver 2 fingers under the rib cage. His clinical
history included a germ line mutation in CDH1 for
which a prophylactic total gastrectomy had been carried
out 2 years prior. Pathological examination of the
resected stomach had revealed a multifocal diffuse
growing poorly differentiated mucus-producing adenocar-
cinoma, with foci varying in size from 1 to 8 mm that
were limited to the lamina propria (intramucosal
carcinoma). Four family members had died of gastric
cancer between the ages of 43 and 56 years. There was
no family history of pancreatic cancer.
A computed tomography scan was performed that
revealed enlarged bile and pancreatic ducts and a mass
in the head of pancreas, suspicious for a malignantpancreatic tumor. A Whipple's pancreatoduodenectomy
was performed. Examination of the resected head of
pancreas revealed a 3-cm mass that, on microscopic
examination, was diagnosed as a moderately to poorly
differentiated PDAC. The malignant process extended into
the duodenal wall and was present less than 1 mm from
the duodenal resection margin. All other resection margins
were free of tumor. Of the 16 excised lymph nodes, 3
contained metastases, warranting the staging T3N1Mx or
IIB. Adjuvant therapy was initiated consisting of several
runs of gemcitabine. However, 3 months later, a computed
tomography scan revealed a recurrent lesion in the
pancreas and multiple lesions in the liver, suspicious for
metastatic tumors, and treatment with curative intent was
ceased. The patient was treated for his pain and discharged
home where he died 2 months later.3. Materials and methods
Paraffin blocks of both the gastric tumor and the PDAC
were obtained. Neoplastic cells from the PDAC were
isolated using manual microdissection. With use of laser
microdissection (Carl Zeiss, Jena, Germany), the malignant
cells of the gastrectomy specimen were isolated from the
lamina propria. Normal gastric epithelium and a non-
malignant lymph node were included as control samples.
Genomic DNA was isolated using the Qiamp DNA minikit
(Qiagen, Venlo, Netherlands) according to manufacturer's
protocol or, in the case of the gastric cells, by direct lyses
with Proteinase K (Roche, Basel, Switzerland).3.1. IHC
IHCwas performed on formalin-fixed, paraffin-embedded
tissue samples as previously described [9]. Two different
E-cadherin antibodies were used: E-cadherin antibody,
dilution 1:100, (ab1416; Abcam, Cambridge, UK), which is
directed at the extracellular part of the protein (exon-8), and
E-cadherin, clone 36, dilution 1:200, (BD Bioscience, Breda,
The Netherlands), which binds the cytoplasmic domain.
3.2. E-cadherin mutation analysis
To confirm the germ line mutation earlier identified and
possibly identify a somatic mutation in the wild type (WT)-
allele, the complete CDH1 gene was sequenced in all
samples. Sequencing was performed as previously described
[9]. Forward and reverse primers for each exon were
designed (sequences available upon request). The sequenc-
ing reaction mix was run on the 3130 Genetic Analyzer
(Applied Biosystems, Carlsbad, CA). Sequences were
analyzed using the CODONCODE ALIGNER software
(Codoncode Corperation, Dedham, MA).
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To evaluate loss of heterozygosity (LOH) of E-cadherin, 1
microsatellite marker was used, located on chromosome
16q22 (D16s2624) around the CDH1 locus. Polymerase
chain reaction (PCR) was performed (primer sequences and
cycling conditions available upon request). Analysis was
carried out using an automated ABI 3130 Genetic Analyzer
(Applied Biosystems) using the GeneScan 500 ROX Size
Standard and the manufacturer's Genescan 3.1.2 software
(Applied Biosystems). LOH was assumed if the allelic
imbalance factor was greater than 1.6 or smaller than 0.6.
3.4. Methylation analysis
A methylation-specific PCR (ms-PCR) reaction was
performed to evaluate promotor methylation of the CDH1
gene using the Epitect Bisulfite kit (Qiagen) according to the
protocol provided by the manufacturer. After bisulfite
treatment, PCR reactions were performed. Primers specific
for either methylated or unmethylated templates were
designed (sequences and cycling conditions available upon
request). Sequencing was performed as described above.
Because ms-PCR did not produce reliable results, another
methylation assay was performed. For this method, the
SALSA MLPA KIT ME004-A1 Tumour Suppressor kit
(MRC-Holland, Amsterdam, The Netherlands) was used.
This kit contains 31 probes that recognize CpG islands in 27
different tumor suppressor genes including CDH1. Analysis
was performed as described by the manufacturer. Genescan
analysis was performed as described above, and samples
were analyzed using the Cofalyzer software (MRC Holland).
3.5. TP53/KRAS2 mutation analysis
To evaluate mutation status of TP53 and KRAS2 in the
PDAC sample, sequencing was performed. Primers for exon
4-9 of TP53 and exon 1-2 of KRAS2 were designed
(sequences and PCR cycling conditions available upon
request). PCR products were purified using a combination of
exonuclease I (Westburg, Leusden, The Netherlands) and
shrimp alkaline phosphatase (GE Healthcare, Chalfont St.
Giles, UK). Sequencing was performed as described above
and analyzed using Mutation Surveyor (Softgenetics, State
College, PA).4. Results
4.1. IHC
Immunohistochemical staining showed the same labeling
pattern for E-cadherin in all gastric tumors. Membranous
staining was clearly diminished compared with the normalepithelium surrounding the malignant cells, suggesting a
defect in E-cadherin signaling in the gastric lesions (Fig. 1C
and D). Cytoplasmic staining was granular and focally
positive. Exon-8 skipping as a second genetic hit, often
observed in sporadic DGC [10], was shown to be absent, as
one of the E-cadherin antibodies used specifically recognized
exon-8. In the PDAC sample, E-cadherin staining was strong
with both antibodies, and there was no decrease in intensity
compared with normal epithelial cells suggesting intact
E-cadherin signaling (Fig. 1E and F).
4.2. Mutation analysis
Mutation analysis for CDH1 did not identify any new
mutations. The germ line mutation detected previously
was confirmed in all samples. The mutation was located
at the splice site of exon 10 and intron 10 and consisted
of an insertion of a T-nucleotide just 2 bases after exon
10: 1565+2insT, as shown in Fig. 1A.
4.3. LOH
To further specify E-cadherin signaling, LOH analysis
was performed. The allelic imbalance factor was calculated
at 1.21 for the gastric tumor samples and 1.00 for the PDAC
sample, confirming the absence of LOH in all samples. In
addition, LOH was ruled out by the mutation analysis of
CDH1, which revealed a heterozygous SNP in exon 13
(RS1801552) in both the gastric and the pancreatic samples.
4.4. Methylation analysis
An ms-PCR did not produce reliable results. Therefore,
another technique, methylation-specific multiplex ligand-
dependent probe-amplification, was tried. Unfortunately,
although this reaction was repeated multiple times, it did not
result in interpretable data either, presumably as the amount
of DNA obtained from the gastric cells was not sufficient to
perform further testing. No E-cadherin promoter methylation
was found in the PDAC.
4.5. Analysis of the PDAC for KRAS2 and TP53
KRAS2 mutation analysis of the PDAC sample revealed a
point mutation in exon 1, codon 12, and G12D. In TP53, a
mutation was found as well. Sequencing of exon 7 revealed
the TAT-TGT missense mutation at codon 238, responsible
for Cys to Tyr substitution (C238T).5. Discussion
Decreased E-cadherin expression has been described in
numerous different types ofmalignancies, including pancreatic
Fig. 1 A, Mutation analysis CDH-1 showing a mutation in exon 10, 1565 +2insT in the patient. Arrow indicates mutation. B, Hematoxylin-
eosin stained gastric resection specimen clearly depicting the DGC cells. C and D, E-cadherin IHC on DGC cells using 2 different antibodies
both showing a clear decrease in membranous staining intensity in the signet ring cells compared with the normal gastric epithelium; granular
cytoplasmic staining is present in the tumor cells. E and F, E-cadherin IHC on the PDAC using 2 different antibodies showing strong
membranous as well as cytoplasmic staining suggesting unaltered E-cadherin expression in the malignant cells.
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have a higher chance of developing pancreatic tumors,
implying that sole loss of E-cadherin expression is not
sufficient to initiate tumorigenesis in the pancreas. Neverthe-
less, there is a strong suggestion that diminished E-cadherin
expression increases invasive potential and worsens prognosisin PDAC [8]. Therefore, it seemed plausible that the germ line
CDH1 mutation in this patient may have played a role in the
development of his pancreatic tumor.
IHC for E-cadherin in the gastric samples showed a
clearly diminished labeling intensity in the malignant cells,
suggesting a defect in E-cadherin signaling. Although we
461Pancreatic ductal adenocarcinoma in HDGCtried to identify the mechanism for the somatic knock out of
theWT-allele in the gastric tumor cells, this was not possible.
Sequencing showed only the previously known germ line
mutation. LOH was also not the cause for the decrease in
E-cadherin expression. Methylation of the promotor, the
most common second genetic hit in HDGC [11], could not
be ruled out because methylation analysis was incomplete
because of technical difficulties. However, the persistent
yet decreased E-cadherin staining in the gastric tumors with
IHC suggests that posttranslational modifications are more
likely to have caused a somatic knock out.
The pattern of E-cadherin staining in the gastric samples
observed with IHC has been described previously. In 2009,
Humar et al [12] found residual activity of E-cadherin in
patients with HDGC, even with a second genetic hit
consisting of promoter methylation. Barber et al [13]
described their search for the mechanism of somatic
inactivation of the wild-type allele and found persistent
yet reduced staining in almost all cases. Remarkably, one of
their cases exhibited a mutation at almost the exact
same location as the patient described above, 1565 + 1G N T,
and similar to the patient described in this case report,
E-cadherin labeling was decreased, yet no LOH or promotor
methylation was identified.
The persistent E-cadherin labeling with IHC with no
evidence of a decrease in intensity clearly showed the
presence of the wild-type allele in the PDAC sample, thereby
excluding CDH1 as a PDAC tumor inducer. This conclusion
can be drawn solely upon the results from the IHC but is
strongly supported by the molecular analyses carried out on
KRAS2 and TP53, as the alterations found in these genes are
characteristic for sporadic PDACs.
As shown by other groups, identifying the second genetic
hit remains difficult in HDGC, and this study emphasizes
once more the value of IHC. Although more elaborate and
refined techniques have been developed, we highlight the
vital importance and relevance of IHC that, with the use of a
reliable antibody, enabled a conclusion to be drawn basedon protein expression. Although the exact mechanism for
E-cadherin loss was not identified, the knowledge that this
did not influence the development of the PDAC is crucial
for the patient's family, physicians, and basic scientists.References
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